R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 39 PLN -1.27% Market Closed
Market Cap: 901.7m PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Ryvu Therapeutics SA
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ryvu Therapeutics SA
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
R
Ryvu Therapeutics SA
WSE:RVU
Operating Income
-zł104.9m
CAGR 3-Years
-13%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
I
Inno-Gene SA
WSE:IGN
Operating Income
-zł2.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-12%
M
Medicofarma Biotech SA
WSE:MDB
Operating Income
-zł2.5m
CAGR 3-Years
-60%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Selvita SA
WSE:SLV
Operating Income
zł51.3m
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ryvu Therapeutics SA
Glance View

Market Cap
901.5m PLN
Industry
Life Sciences Tools & Services

Ryvu Therapeutics SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 186 full-time employees. The company went IPO on 2011-07-14. The firm is active in the pharmaceutical and biotechnology fields. The company operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. The company operates through unit Ardigen SA and SORS Holdings Ltd.

RVU Intrinsic Value
42.31 PLN
Undervaluation 8%
Intrinsic Value
Price
R

See Also

What is Ryvu Therapeutics SA's Operating Income?
Operating Income
-104.9m PLN

Based on the financial report for Sep 30, 2024, Ryvu Therapeutics SA's Operating Income amounts to -104.9m PLN.

What is Ryvu Therapeutics SA's Operating Income growth rate?
Operating Income CAGR 5Y
-19%

Over the last year, the Operating Income growth was -44%. The average annual Operating Income growth rates for Ryvu Therapeutics SA have been -13% over the past three years , -19% over the past five years .

Back to Top